LONE TREE, COLORADO — Cochlear Limited (ASX: COH) today announced FDA clearance of the new Cochlear ® Osia ® 3 Sound Processor, the latest generation of its Osia ® bone conduction hearing system. ‡ Cochlear’s bone conduction hearing solutions are designed for children and adults with conductive hearing loss, mixed hearing loss, and single-sided deafness (SSD). Key Features of the Osia 3 Sound Processor Rechargeable
No actionable clinical change; this is a product launch announcement — audiologists who fit bone conduction systems should note the new rechargeable and connectivity options when counseling eligible patients.
The Osia 3 expands the rechargeable bone-anchored hearing system market, which may influence device selection conversations in clinics that fit patients with conductive or single-sided deafness.
- 01Cochlear Limited received FDA clearance for the Osia 3 Sound Processor.
- 02Key upgrades include rechargeable battery technology and enhanced wireless connectivity.
- 03Osia 3 is the latest generation of Cochlear's active osseointegrated (bone-anchored) system.
- 04No independent clinical performance data are presented in this announcement.
The Osia 3 features rechargeable technology compared to its predecessor.
press releasepromotionalThe Osia 3 has received FDA clearance.
press releasesupportedThe Osia 3 offers enhanced connectivity over previous generations.
press releasepromotional